JRJulia Ritterhoff

Julia Ritterhoff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julia Ritterhoff has a total of 122 co-authors. Here are the top co-authors by number of shared publications:

  • Patrick Most

    German Centre for Cardiovascular Research (DZHK), Partner site Heidelberg/Mannheim, Heidelberg, Germany; Department of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany; Division of Molecular and Translational Cardiology, University Hospital Heidelberg, Heidelberg, Germany

    5 shared publications
  • Rong Tian

    Mitochondria and Metabolism Center, Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, WA

    5 shared publications
  • Andreas Jungmann

    Division of Molecular and Translational Cardiology (D.Z., M.B., S.G., H.W., A.K.S., D.K., M.Q., A.J., J.R., P.M.), University Hospital Heidelberg, Germany

    4 shared publications
  • Andreas Seitz

    Molecular and Translational Cardiology, Department of Internal Medicine III, Heidelberg University Hospital, Heidelberg, Germany

    3 shared publications
  • Hugo Albert Katus

    Department of Cardiology, Pulmonology and Angiology, University Hospital Heidelberg, Heidelberg, Germany

    3 shared publications
  • Mirko Völkers

    Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany

    3 shared publications

Latest Publications

  • Generation of Human Cardiomyocytes With Adult-Like Metabolism by a Chemically Defined Medium for Mitochondrial Disease Modeling

    by Chengyi Tu, Arianne Caudal, Yu Liu, Nadjet Belbachir, Ana Kojic, Brett Stern, Lu Ren, Erin Hu, Nathan Cunningham, Brian Yu, et al.

    BACKGROUND: Human induced pluripotent stem cell (iPSC)–derived cardiomyocytes (iPSC cardiomyocytes) as a model for cardiac disease have become increasingly important, bolstered by the Food and Drug Administration’s initiative to promote novel alternative methods for biomedical research. A key limitation of metabolically immature iPSC cardiomyocytes is their limited ability to accurately recapitulate mitochondria-dependent pathologies, such as Friedreich ataxia–associated cardiomyopathy. Adult cardiomyocytes are characterized by a high density of interfibrillar mitochondria, abundant respiratory complexes (I–V) that form supercomplexes, and efficient utilization of fatty acids to drive mitochondrial respiration. These unique metabolic structures and functions are largely missing in iPSC cardiomyocytes. Further, whether iPSC cardiomyocytes can efficiently utilize fatty acids for respiration in the presence of glucose, a unique adult feature, remains unclear. METHODS: We developed a chemically defined, 11-component maturation medium (MM11) designed using a bioinformatics-guided strategy that identified high-fidelity transcriptional markers of adult cardiac metabolic maturity. Human iPSC cardiomyocytes were treated with MM11 for 2 weeks and evaluated at the molecular, structural, and functional levels, with an emphasis on mitochondrial maturity. We benchmarked our results with isolated primary adult human cardiomyocytes. Last, we tested whether this method could enable us to more accurately model Friedreich ataxia cardiomyopathy. RESULTS: MM11 treatment increased expression of metabolic pathways, including mitochondrial respiration and fatty acid metabolism, at the transcript and protein levels. Ultrastructural analyses revealed the formation of interfibrillar mitochondria and mitochondrial respiratory supercomplexes, a feature never shown in previous reports. Functionally, MM11-treated iPSC cardiomyocytes exhibited substantially increased oxidative phosphorylation and a metabolic preference for fatty acid utilization in the presence of physiologic substrates, as determined by oxygen consumption assays and 13 C isotope tracing. CONCLUSIONS: MM11 promotes robust metabolic maturation of human iPSC cardiomyocytes, enabling sophisticated mitochondrial architecture and substrate utilization. These metabolically matured cardiomyocytes more faithfully model mitochondria-dependent cardiac pathologies, including ischemia-reperfusion injury and Friedreich ataxia cardiomyopathy, improving the use of iPSC cardiomyocytes for mechanistic studies of human heart disease.

  • The burn repair molecule? Evaluating FGF-21 in thermal injury – A systematic review

    by Tobias Niederegger, Thomas Schaschinger, Jule Brandt, Leonard Knoedler, Samuel Knoedler, Alen Palackic, Felix J. Klimitz, Dorothea Noll, Patrick Most, Julia Ritterhoff, et al.


  • Open Access

    Novel Human Heart–Derived Natural Adeno-Associated Virus Capsid Combines Cardiospecificity With Cardiotropism In Vivo

    by Daniel Zeissler, Martin Busch, Sebastian Grieskamp, Eric Meinhardt, Hanna Wurzer, Shubhada R. Kulkarni, Anna K. Schrattel, Stephanie Molter, Dorothea Kehr, Maria Qatato, et al.


  • Open Access

    Cardiac-Targeted AAV5-S100A1 Gene Therapy Protects Against Adverse Remodeling and Contractile Dysfunction in Postischemic Hearts

    by Dorothea Kehr, Janek Salatzki, Birgit Seger, Karl Varadi, Jennifer Birkenstock, Philipp Schlegel, Erhe Gao, Walter J. Koch, Hugo A. Katus, Norbert Frey, et al.

    BACKGROUND: Guided by long-term safety data for AAV5 (adeno-associated virus 5) in humans, our translational study investigated whether AAV5 effectively delivers genes to healthy and achieves therapeutic efficacy in dysfunctional human-sized hearts, using a clinically applicable mode of administration and vector dosages. METHODS: AAV-mediated cardiac gene transfer in pigs was performed by percutaneous catheter-based retrograde intravenous vector delivery, and vector genome and transgene expression levels determined by reverse transcription-polymerase chain reaction and immunoblotting. Postmyocardial infarction (MI) cardiac dysfunction porcine and murine models were generated by coronary catheter-based occlusion and ligation, respectively. The study end points left ventricular ejection fraction and left ventricular MI size, were measured by cardiac magnetic resonance imaging and echocardiography. Bulk myocardial RNA-sequencing and weighted gene correlation network analysis were used to link study end points to molecular pathway mechanisms. Safety was assessed by clinical chemistry, blood count and ECG. RESULTS: In a first biodistribution study, AAV5 (1×10 13 vector genomes; vgs) with the reporter gene luciferase ( luc ) achieved broad and homogenous transduction of healthy pig hearts 30 days after catheter-based retrograde intravenous vector delivery without toxicity. Both its myocardial and extra-cardiac distribution patterns were advantageous compared with AAV9- luc and AAV6- luc . Using AAV5 with the cardioprotective human gene S100A1 ( hS100A1 ; 1×10 13 vgcs) by catheter-based retrograde intravenous vector delivery in a subsequent therapy study in post-MI pigs prevented left ventricular MI extension and improved left ventricular ejection fraction after 3 months without clinical toxicity. Weighted gene correlation network analysis linked novel antiinflammatory actions and cardioprotective signaling mechanisms by hS100A1 to study end point improvements, which was confirmed in a post-MI mouse model. CONCLUSIONS: Providing the clinically relevant proof of concept for AAV5 to effectively transduce healthy and dysfunctional human-sized hearts, its clinical long-term safety, scalable producibility, and low preexisting immunity in humans may predestine AAV5 as an effective and safe gene carrier for a prevalent disease such as chronic heart failure, using therapeutic genetic effectors such as hS100A1 or others.


  • Open Access

    S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models

    by Dorothea Kehr, Julia Ritterhoff, Manuel Glaser, Lukas Jarosch, Rafael E. Salazar, Kristin Spaich, Karl Varadi, Jennifer Birkenstock, Michael Egger, Erhe Gao, et al.

    BACKGROUND: The EF-hand Ca 2+ sensor protein S100A1 has been identified as a molecular regulator and enhancer of cardiac performance. The ability of S100A1 to recognize and modulate the activity of targets such as SERCA2a (sarcoplasmic reticulum Ca 2+ ATPase) and RyR2 (ryanodine receptor 2) in cardiomyocytes has mostly been ascribed to its hydrophobic C-terminal α-helix (residues 75–94). We hypothesized that a synthetic peptide consisting of residues 75 through 94 of S100A1 and an N-terminal solubilization tag (S100A1ct) could mimic the performance-enhancing effects of S100A1 and may be suitable as a peptide therapeutic to improve the function of diseased hearts. METHODS: We applied an integrative translational research pipeline ranging from in silico computational molecular modeling and in vitro biochemical molecular assays as well as isolated rodent and human cardiomyocyte performance assessments to in vivo safety and efficacy studies in small and large animal cardiac disease models. RESULTS: We characterize S100A1ct as a cell-penetrating peptide with positive inotropic and antiarrhythmic properties in normal and failing myocardium in vitro and in vivo. This activity translates into improved contractile performance and survival in preclinical heart failure models with reduced ejection fraction after S100A1ct systemic administration. S100A1ct exerts a fast and sustained dose-dependent enhancement of cardiomyocyte Ca 2+ cycling and prevents β-adrenergic receptor–triggered Ca 2+ imbalances by targeting SERCA2a and RyR2 activity. In line with the S100A1ct-mediated enhancement of SERCA2a activity, modeling suggests an interaction of the peptide with the transmembrane segments of the sarcoplasmic Ca 2+ pump. Incorporation of a cardiomyocyte-targeting peptide tag into S100A1ct (cor-S100A1ct) further enhanced its biological and therapeutic potency in vitro and in vivo. CONCLUSIONS: S100A1ct is a promising lead for the development of novel peptide-based therapeutics against heart failure with reduced ejection fraction.


  • Open Access

    13C stable isotope tracing reveals distinct fatty acid oxidation pathways in proliferative versus oxidative cells

    by Julia Ritterhoff, Timothy McMillen, Hanna Foundas, Roland Palkovacs, Gernot Poschet, Arianne Caudal, Yaxin Liu, Patrick Most, Matthew Walker, Rong Tian

    By using 13C stable isotope-resolved metabolomics and FA-driven oxygen consumption rate analysis, our study provides novel insights into the fate of FA carbon through β-oxidation and downstream TCA cycle in proliferative and oxidative cells. Although both proliferative and oxidative cells demonstrate robust β-oxidation, they demonstrate distinct metabolic carbon fate downstream of citrate during TCA cycle oxidation. This differential TCA cycle engagement is likely to be important to balance catabolic and anabolic demands of the cell.


  • Open Access

    S100A1’s single cysteine is an indispensable redox switch for the protection against diastolic calcium waves in cardiomyocytes

    by Andreas Seitz, Martin Busch, Jasmin Kroemer, Andrea Schneider, Stephanie Simon, Andreas Jungmann, Hugo A. Katus, Patrick Most, Julia Ritterhoff

    S100A1 is an emerging candidate for future gene-therapy treatment of human chronic heart failure. We aimed to study the significance of the conserved single-cysteine 85 (C85) residue in cardiomyocytes. We show that S100A1 is endogenously glutathionylated in the heart and demonstrate that this is dispensable to increase systolic Ca2+ transients, but indispensable for mediating S100A1’s protection against sarcoplasmic reticulum (SR) Ca2+ waves, which was dependent on the ryanodine receptor 2 (RyR2) nitrosylation status.


  • Raising NAD + Level Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation

    by Matthew A. Walker, Hongye Chen, Aprajita Yadav, Julia Ritterhoff, Outi Villet, Tim McMillen, Yuliang Wang, Hayley Purcell, Danijel Djukovic, Daniel Raftery, et al.

    BACKGROUND: Strategies to increase cellular NAD + (oxidized nicotinamide adenine dinucleotide) level have prevented cardiac dysfunction in multiple models of heart failure, but molecular mechanisms remain unclear. Little is known about the benefits of NAD + -based therapies in failing hearts after the symptoms of heart failure have appeared. Most pretreatment regimens suggested mechanisms involving activation of sirtuin, especially Sirt3 (sirtuin 3), and mitochondrial protein acetylation. METHODS: We induced cardiac dysfunction by pressure overload in SIRT3-deficient (knockout) mice and compared their response with nicotinamide riboside chloride treatment with wild-type mice. To model a therapeutic approach, we initiated the treatment in mice with established cardiac dysfunction. RESULTS: We found nicotinamide riboside chloride improved mitochondrial function and blunted heart failure progression. Similar benefits were observed in wild-type and knockout mice. Boosting NAD + level improved the function of NAD(H) redox-sensitive SDR (short-chain dehydrogenase/reductase) family proteins. Upregulation of Mrpp2 (mitochondrial ribonuclease P protein 2), a multifunctional SDR protein and a subunit of mitochondrial ribonuclease P, improves mitochondrial DNA transcripts processing and electron transport chain function. Activation of SDRs in the retinol metabolism pathway stimulates RXRα (retinoid X receptor α)/PPARα (proliferator-activated receptor α) signaling and restores mitochondrial oxidative metabolism. Downregulation of Mrpp2 and impaired mitochondrial ribonuclease P were found in human failing hearts, suggesting a shared mechanism of defective mitochondrial biogenesis in mouse and human heart failure. CONCLUSIONS: These findings identify SDR proteins as important regulators of mitochondrial function and molecular targets of NAD + -based therapy. Furthermore, the benefit is observed regardless of Sirt3-mediated mitochondrial protein deacetylation, a widely held mechanism for NAD + -based therapy for heart failure. The data also show that NAD + -based therapy can be useful in pre-existing heart failure.


  • Wird KI neue Medikamente gegen Herzkrankheiten hervorbringen?

    by Manuel Glaser, Julia Ritterhof, Patrick Most, Rebecca C. Wade

    Zusammenfassung: Angesichts der umwälzenden Auswirkungen, die künstliche Intelligenz (KI) auf Wissenschaft, Medizin und darüber hinaus hat, betrachten wir hier das Potenzial von KI für die Entdeckung neuer Medikamente gegen Herzkrankheiten. Wir definieren KI im weitesten Sinne als den Einsatz von maschinellem Lernen, einschließlich Statistik und Deep Learning, um Muster in Datensätzen zu erkennen, die für Vorhersagen genutzt werden können. Jüngste Durchbrüche in der Fähigkeit, sehr große Datenmengen zu berücksichtigen, haben einen Boom in der KI-gestützten Arzneimittelentdeckung sowohl in der Wissenschaft als auch in der Industrie ausgelöst. Viele neue Unternehmen verfügen bereits über Arzneimittel-Pipelines, die bis in die klinische Erprobung reichen, aber noch keine Medikamente gegen Herzkrankheiten enthalten. Wir beschreiben hier den Einsatz von KI für die Entdeckung von niedermolekularen Medikamenten und Biologika, einschließlich therapeutischer Peptide, sowie für die Vorhersage von Wirkungen wie Kardiotoxizität. Der konzertierte Einsatz von KI zusammen mit physikbasierten Simulationen und experimentellen Rückkopplungsschleifen wird notwendig sein, um das Potenzial der KI für die Arzneimittelentdeckung und die Entwicklung von Präzisionsarzneimitteln für Herzkrankheiten voll auszuschöpfen.

  • Open Access

    S100A1’s single cysteine is an indispensable redox-switch for the protection against diastolic calcium leakage in cardiomyocytes

    by Andreas Seitz, Martin Busch, Jasmin Kroemer, Andrea Schneider, Stephanie Simon, Andreas Jungmann, Hugo A. Katus, Julia Ritterhoff, Patrick Most

    The EF-hand calcium (Ca 2+ ) sensor protein S100A1 combines inotropic with antiarrhythmic potency in cardiomyocytes (CM). Oxidative posttranslational modification (ox-PTM) of S100A1’s conserved, single cysteine residue (C85) via reactive nitrogen species (i.e. S-nitrosylation or glutathionylation) was proposed to modulate conformational flexibility of intrinsically disordered sequence fragments and to increase the molecule’s affinity towards Ca 2+ . In light of the unknown biological functional consequence, we aimed to determine the impact of the C85 moiety of S100A1 as a potential redox-switch. We first uncovered that S100A1 is endogenously glutathionylated in the adult heart in vivo. To prevent glutathionylation of S100A1, we generated S100A1 variants that were unresponsive to ox-PTMs. Overexpression of wildtype (WT) and C85-deficient S100A1 protein variants in isolated CM demonstrated equal inotropic potency, as shown by equally augmented Ca 2+ transient amplitudes under basal conditions and β-adrenergic receptor (βAR) stimulation. However, in contrast ox-PTM defective S100A1 variants failed to protect against arrhythmogenic diastolic sarcoplasmic reticulum (SR) Ca 2+ leak and ryanodine receptor (RyR2) hypernitrosylation during β-AR stimulation. Despite diastolic performance failure, C85-deficient S100A1 protein variants exerted similar Ca 2+ -dependent interaction with the RyR2 than WT-S100A1. Dissecting S100A1’s molecular structure-function relationship, our data indicate for the first time that the conserved C85 residue potentially acts as a redox-switch that is indispensable for S100A1’s antiarrhythmic but not its inotropic potency in CM. We therefore propose a model where C85’s ox-PTM determines S100A1’s ability to beneficially control diastolic but not systolic RyR2 activity.